VICTORIA, BC, Aug. 13, 2020 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB:
IPATF) (FSE:TQB2), a provider of best-in-class therapeutic antibody
capabilities announces that it has retained Crescendo
Communications, LLC ("Crescendo") as its investor relations firm to
help broaden awareness of the Company within the North American
financial markets.
David Waldman, President and CEO
of Crescendo, commented, "ImmunoPrecise has developed a broad
portfolio of therapeutic antibodies that bind to multiple regions
of the SARS-CoV-2 spike protein. We are excited about the
potential of these antibodies, which have already achieved nearly
complete neutralization of SARS-CoV-2 in combination studies.
We are honored to support the company in combatting this global
pandemic and look forward to helping increase awareness within the
investment community, especially in the U.S."
The investor relations agreement is for a renewable three-month
term and may be terminated by either party by giving 30 days
written notice of such termination. The Company has granted
Crescendo 250,000 incentive options to purchase common shares of
the Company at a price of $1.50 per
share for a period of 3 years. The options are subject to following
vesting period: 25% at three months after the date of grant and 25%
every three months thereafter. The options will be granted in
accordance with the Company's stock option plan and as set forth by
TSX Venture Exchange policy. Both the options and the
investor relations consulting agreement are subject to the approval
of the TSX Venture Exchange
About Crescendo Communications, LLC
Crescendo Communications, LLC, headquartered in New York City with offices and affiliates in
Europe and Asia, is an emerging leader within the
investor relations industry. The principals of Crescendo have
represented hundreds of companies across all market caps and
industries. The firm was founded on a strategic and professional
approach to investor relations that builds awareness of public
companies through tailored outreach programs that target
institutional investors, analysts, and the financial media.
Our approach is centered around properly educating investors
and cultivating trust in order to uphold and protect our clients'
long-term credibility and reputation on Wall Street.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
company utilizing species agnostic, multi-format, characterized and
engineered, human monoclonal antibodies, on an abbreviated
timeframe. For further information, visit www.immunoprecise.com or
contact solutions@immunoprecise.com.
Forward Looking Information
This news release contains statements that, to the extent they
are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend",
"should" and similar expressions to identify forward-looking
statements. Any such forward-looking statements are based on
assumptions and analyses made by ImmunoPrecise in light of its
experience and its perception of historical trends, current
conditions and expected future developments. However, whether
actual results and developments will conform to ImmunoPrecise's
expectations and predictions is subject to any number of risks,
assumptions and uncertainties. Many factors could cause
ImmunoPrecise's actual results to differ materially from those
expressed or implied by the forward-looking statements contained in
this news release. Such factors include, among other things, actual
revenues and earnings for IPA being lower than anticipated, and
those risks and uncertainties described in ImmunoPrecise's annual
management discussion and analysis for the previous quarter ended
January 31, 2020 which can be
accessed at www.sedar.com. The "forward-looking statements"
contained herein speak only as of the date of this press release
and, unless required by applicable law, ImmunoPrecise undertakes no
obligation to publicly update or revise such information, whether
as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.